ISPH shares likely to settle around $4, says Leerink Leerink finds the denufosol trial failure as highly unexpected and expects ire Pharma shares to settle around $4. The firm estimates Inspire's eye drugs business at roughly $3 per share and the company's cash position at $1 per share
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.